SCHEMBL4474247

SCHEMBL4474247

CCOC(=O)C1(CNc2ccc(OC)c(C)c2C)CCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ GAA P10253 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MEN1 O00255 6/20 0.37
▸ POLB P06746 3/20 0.37
▸ TUBB4A P04350 2/20 0.37
▸ TUBB P07437 2/20 0.37
▸ TUBA3C P0DPH7 2/20 0.37
▸ TUBA1B P68363 2/20 0.37
▸ TUBA4A P68366 2/20 0.37
▸ TUBB4B P68371 2/20 0.37
▸ TUBB3 Q13509 2/20 0.37
▸ TUBB2A Q13885 2/20 0.37
▸ TUBB8 Q3ZCM7 2/20 0.37
▸ TUBA3E Q6PEY2 2/20 0.37
▸ TUBA1A Q71U36 2/20 0.37
▸ TUBA1C Q9BQE3 2/20 0.37
▸ TUBB6 Q9BUF5 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477154 0.82 ALDH1A1 (0.35) KMT2AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL20482698 0.71 KMT2A (0.64) KMT2AALDH1A1GAAMAPTMEN1
SCHEMBL14749776 0.71 L3MBTL1 (0.42) KMT2AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL15692863 0.69 HSD11B1 (0.58) KMT2AALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL16839666 0.69 TUBB4A (0.43) KMT2AALDH1A1GAASMN1; SMN2MEN1
SCHEMBL23586916 0.69 SMN1; SMN2 (0.40) KMT2AALDH1A1GAASMN1; SMN2MEN1
SCHEMBL4778825 0.69 PDE4B (0.43) KMT2AALDH1A1GAAMAPTMEN1
SCHEMBL4465848 0.68 TP53 (0.34) KMT2AALDH1A1MEN1POLBL3MBTL1
Hydrochloric Acid SCHEMBL14999713 0.67 PDE4B (0.42) KMT2AALDH1A1GAAMAPTMEN1
SCHEMBL29101205 0.66 CYP4F2 (0.38) KMT2AALDH1A1GAASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 — — US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 — — EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 — — WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 KMT2A 3967/4885ALDH1A1 169/4885GAA 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback